Tower Research Capital LLC (Trc) Akero Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 16,188 shares of AKRO stock, worth $814,094. This represents 0.01% of its overall portfolio holdings.
Number of Shares
16,188
Previous 1,859
770.79%
Holding current value
$814,094
Previous $53,000
749.06%
% of portfolio
0.01%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding AKRO
# of Institutions
196Shares Held
74.9MCall Options Held
210KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.38MShares$371 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$356 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$298 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$281 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$263 Million5.21% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.33B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...